{"filing":{"accession_number":"0001404644-26-000044","cik":"0001404644","ticker":"NGNE","company_name":"Neurogene Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"ngne-20260608.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/ngne-20260608.htm"},"events":[{"id":6274,"run_id":5498,"accession_number":"0001404644-26-000044","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Neurogene announced completion of dosing in its EmboldenTM registrational trial for NGN-401 in Rett syndrome treatment. This is a material clinical development milestone for a gene therapy company, as completion of a Phase 3 registrational trial dosing is a significant de-risking event that affects investor assessment of the company's pipeline and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined event types), warranting classification as other_material.","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5055,"accession_number":"0001404644-26-000044","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Neurogene announced completion of dosing in its EmboldenTM registrational trial for NGN-401 in Rett syndrome treatment. This is a material clinical development milestone for a gene therapy company, as completion of a Phase 3 registrational trial dosing is a significant de-risking event that affects investor assessment of the company's pipeline and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined event types), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:34:06.223671+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5055,"accession_number":"0001404644-26-000044","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Neurogene announced completion of dosing in its EmboldenTM registrational trial for NGN-401 in Rett syndrome treatment. This is a material clinical development milestone for a gene therapy company, as completion of a Phase 3 registrational trial dosing is a significant de-risking event that affects investor assessment of the company's pipeline and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined event types), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:34:06.223671+00:00","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-06-08"}]}